Necitumumab ELISA Kit|Necitumumab ELISA试剂盒(靶标：)
- 货号：RB9TDF004038
- 价格：面议
- 点击：477
产品介绍
产品参数
| 应用 | ELISA |
|---|---|
| 检测方法 | Colorimetric |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 样本类型 | Plasma, Serum |
| 检测类型 | Quantitative |
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 运输条件 | 2-8 ℃ |
| 登录号 | P00533 |
| 背景信息 | Necitumumab (IMC-11F8, LY3012211) is a second-generation fully human immunoglobulin (Ig) G1 kappa isotype monoclonal antibody (mAb) that acts as an antagonist to direct against the extracellular region of epidermal growth factor receptor (EGFR). It was developed by Eli Lilly & Co (Indianapolis, IN, USA) and produced in genetically engineered mammalian NS0 cells. It was first approved by the U.S. Food and Drug Administration (FDA) under the brand name Portrazza in 2015, for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). After that, it has gained the approval for marketing in the Europe Union and Japan respectively in 2016 and 2017. It is not indicated for treatment of non-squamous NSCLC. Currently, there are several ongoing clinical trials investigating necitumumab in the treatment of NSCLC in several di铿€erent settings. It is currently being studied in combination with pre-existing agents, such as osimertinib, pembrolizumab, nabpaclitaxel, and carboplatin, as well as with new agents under investigation, abemaciclib and AZD9291. Necitumumab is currently being evaluated in the second-line setting following treatment failure or progression with front-line EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy. |
| 别名 | 11F8, IMC-11F8, LY3012211, 906805-06-9 |
| 备注 | For Research Use Only. |
相关产品: